Aripiprazole in the Treatment of Bipolar Depression

Not Applicable

Completed

• Conditions: Bipolar Disorder
• Interventions: Drug: Aripiprazole

• Registration Number: NCT00226317
• Lead Sponsor: Cambridge Health Alliance

Brief Summary

A systematic open-label prospective pilot study to assess aripirazole for acute bipolar depression, with a secondary assessment of longer-term mood stabilization.

Detailed Description

Study is 6 weeks long with 7 clinical visits.

Study Timeline

• Study Start: 2004-04
• Study First Submitted: 2005-09-12
• Study First Submitted QC: 2005-09-26
• Study First Posted: 2005-09-27
• Primary Completion: 2007-12
• Study Completion: 2008-02
• Status Verified: 2017-04
• Last Update Submitted: 2017-04-17
• Last Update Posted: 2017-04-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• DSM-IV diagnosis of bipolar disorder, any subtype; MADRS >16; MRS < 10; not currently taking other mood stabilizers; women of reproductive potential must use an acceptable method of birth control

Exclusion Criteria

• Current substance abuse within past month; serious unstable medical condition; active suicidal ideation; pregnant, trying to become pregnant, or nursing; intent to continue or initiate herbal preparations

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Aripiprazole in depression treatment	Aripiprazole	-

Primary Outcome Measures

Name	Time	Method
Depression state	6 week study

Trial Locations

Locations (1)

Cambridge Health Alliance; 🇺🇸 Cambridge, Massachusetts, United States